Immune to Cancer: The CRI Blog
-
Previewing the 2018 Rational Combinations 360 Conference
The third installment of the Rational Combinations 360 conference, which will be held in Philadelphia September 13-14,…
-
Partner Spotlight: Rafael Amado, Adaptimmune
We introduce you to Rafael Amado, MD, chief medical officer at Adaptimmune, a leader in T cell…
-
Partner Spotlight: Thomas Hudson, Abbvie
We introduce you to Thomas Hudson, MD, vice president, head of oncology discovery and early development at…
-
How Man’s Best Friend Could Help Us Cure Cancer
Cancer very is similar in dogs and humans, and scientists are now exploring how cures for one…
-
Immunotherapy is Here to Stay: Looking Back at this Year’s Breakthroughs
Important immunotherapy breakthroughs benefited patients immensely in 2017 and paved the way for even more advances in…
-
Corporate Social Responsibility Gives Cancer Immunotherapy Research a “Wonderful Edge”
Cupid Intimates spearheaded a corporate social responsibility initiative that generated a $10,000 donation to CRI’s immunotherapy research…
-
CICON17 Day 1 Recap: Neoantigens, Vaccines, and Overcoming Immunotherapy Resistance
Day 1 of CICON17 explored how to identify and target neoantigens with vaccines and other strategies to…
-
Highlights of the 2nd Annual Rational Combinations 360° Conference
Biomarkers will be crucial to taking advantage of combination immunotherapy’s full potential
-
CRI, LRF Team Up to Improve How Doctors Assess Lymphoma Patients Treated with Immunotherapy
LYRIC might provide a better way to gauge immunotherapy responses in lymphoma patients. Clinical trials are essential…